Evaluation of the Potential Effects of LRP5 and Tph1 in the Pathogenesis of Periodontal Disease Individuals With Stage III Grade B Periodontitis

NCT06933797 | Completed

• 2 other identifiers: 36290600/03/20241919B012319473
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: The aim of this study was to determine the changes in LRP5 and TPH1 levels in serum and saliva samples due to periodontal inflammation and to evaluate the relationship between these values and clinical periodontal parameters. Methods: Saliva and serum samples were collected from 20 systemically healthy patients with Stage III periodontitis and 20 periodontally healthy control individuals. Salivary and serum LRP5 and TPH1 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters, including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL), were recorded.

Conditions

Periodontal Disease; Periodontitis (Stage 3); Periodontitis Stage III

Keywords

Low-density lipoprotein receptor-associated protein 5; Tryptophan Hydroxylase 1; Periodontitis

Outcome Measures

Primary Outcomes (2)

• LRP5

  Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) is a WNT coreceptor in the LRP superfamily involved in a wide range of biological processes including endocytosis, cellular communication, lipid homeostasis and embryonic development. The levels of LRP5 in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.

  1 month

• TPH1

  The inhibitory, irreversible enzyme of serotonin synthesis from intestinal cells is tryptophan hydroxylase 1 (TPH1). The levels of TPH1 in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.

  1 month

Study Arms (2)

Stage III periodontitis

Individuals exhibiting pocket depths of \>3 mm in at least two non-adjacent teeth, radiographic evidence of alveolar bone loss extending to the middle or apical third of the root, and tooth loss of ≤4 due to periodontitis were classified as having Stage III periodontitis. The additional criterion for Grade B classification was defined as a % bone loss/age ratio of 0.25-1.

Periodontally healthy

Individuals with no signs of alveolar bone loss and an overall oral bleeding score \<10% were categorized as periodontally healthy.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consisted of patients with stage III periodontitis and periodontally healthy patients admitted to Ankara University Faculty of Dentistry Clinic.

You may qualify if:

• \>18 years old,
• At least 16 permanent teeth except 3rd molars,
• Individuals who do not use orthodontic appliances,
• Individuals who are not pregnant or lactating,
• Individuals without any systemic disease that may affect periodontal health,
• Systemically healthy individuals,
• Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have not received periodontal treatment in the last 1 year

You may not qualify if:

• Pregnant/lactating individuals,
• Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have undergone periodontal treatment in the last 1 year,
• Individuals with psychiatric illness,
• Individuals with any oral infection,
• Individuals with \<16 teeth, excluding molars,
• Individuals with alcohol dependence,
• Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
• Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Sponsors & Collaborators

• Ankara University: lead
• The Scientific and Technological Research Council of Turkey: collaborator

Study Sites (1)

Ankara University, Faculty of Dentistry,

Ankara, Yenimahalle, 06500, Turkey (Türkiye)

Location

Related Publications (2)

• Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008 Nov 28;135(5):825-37. doi: 10.1016/j.cell.2008.09.059.

  PMID: 19041748 BACKGROUND

• Jiang H, Xi Y, Jiang Q, Dai W, Qin X, Zhang J, Jiang Z, Yang G, Chen Q. LRP5 Down-Regulation Exacerbates Inflammation and Alveolar Bone Loss in Periodontitis by Inhibiting PI3K/c-FOS Signalling. J Clin Periodontol. 2025 Apr;52(4):637-650. doi: 10.1111/jcpe.14112. Epub 2025 Jan 21.

  PMID: 39837316 BACKGROUND

MeSH Terms

Conditions

Periodontal Diseases; Periodontitis

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: DDS

Study Record Dates

• First Submitted: April 8, 2025
• First Posted: April 18, 2025
• Study Start: April 1, 2024
• Primary Completion: October 1, 2024
• Study Completion: February 25, 2025
• Last Updated: April 18, 2025

Record last verified: 2025-04

Locations

TU (1)